Tango Therapeutics Q1 2024 Earnings Report $3.10 +0.16 (+5.44%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast Tango Therapeutics EPS ResultsActual EPS-$0.35Consensus EPS -$0.31Beat/MissMissed by -$0.04One Year Ago EPSN/ATango Therapeutics Revenue ResultsActual Revenue$6.47 millionExpected Revenue$7.13 millionBeat/MissMissed by -$660.00 thousandYoY Revenue GrowthN/ATango Therapeutics Announcement DetailsQuarterQ1 2024Date5/8/2024TimeN/AConference Call ResourcesPress ReleaseTNGX Earnings HistoryPowered by Buy this coin BEFORE Inauguration Day … (Ad)Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Tango Therapeutics Earnings HeadlinesBrokerages Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $13.14December 13, 2024 | americanbankingnews.comTango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | businesswire.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 21, 2024 | Crypto Swap Profits (Ad)Tango Therapeutics price target lowered to $8 from $16 at B. RileyNovember 11, 2024 | markets.businessinsider.comPositive Outlook for Tango Therapeutics: Promising TNG462 Data and Strategic FocusNovember 10, 2024 | markets.businessinsider.comPromising Developments and Strategic Shifts at Tango Therapeutics: A Buy Rating with a $13 Price TargetNovember 9, 2024 | markets.businessinsider.comSee More Tango Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tango Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tango Therapeutics and other key companies, straight to your email. Email Address About Tango TherapeuticsTango Therapeutics (NASDAQ:TNGX), a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.View Tango Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
